TTP has been working with clients to design and develop medical devices for over 30 years. Our multi-disciplinary team has completed numerous parenteral developments for pharma companies with our projects routinely covering front-end innovation and product definition through to industrialisation support.
From simple and standalone to complex and connected, come to our stand 430 to start the conversation.
For more information visit the DDL2017 event website.
Looking ahead it won’t be about the drug or even the combination of drug and device; with the introduction of value-based healthcare the way in which therapies are evaluated will change. TTP understands this complexity and we are working with our clients to engineer outcomes.
Adherence can make the difference between product success and product failure. In order for people to adhere, they have to be both able and motivated to use the device. Human factors engineering has gone a long way towards making devices easier to use, but designing for motivation is still in its infancy. TTP has identified principles for how motivation and engagement could be designed into products to improve adherence.
As connectivity becomes a central component of healthcare, TTP is working with its clients to overcome the challenges and deliver meaningful and valuable solutions to the markets. A common early decision is whether to add sensing/connectivity to an existing device or integrate in a new device (with many intermediate options possible). From navigating healthcare economics and driving patient engagement, to addressing data security and developing ultra-low power devices, TTP has been at the forefront of development for 30 years.
Aerosol science is key to targeted delivery to the lungs or nose. The spray characteristics directly impact the deposition profile, whether the formulation is in dry powder, pressurised gas, or liquid form. Having an ability to engineer the particle size distribution, delivery time, and plume properties is fundamental to successful product development.
TTP has invented a range of aerosol technologies and successfully integrated these into inhalers and nebulisers. Along the way, we have developed capabilities to relate fundamental working principles to engineering performance indicators, in-vitro performance and in-vivo results. We are applying these skills and experience in the development of the next generation of inhaled drug delivery devices.
TTP’s robust device design approach extends all the way from incorporating a deep understanding of the users through human factors to advancing engagement with manufacturing partners.
At the core of our technical and design work, we avoid complexity with clever concepts; we support decision making with scientific models, and we anticipate manufacturability and reliability performance through probabilistic design. The latter extends beyond traditional tolerance analyses to predicting functional performance through mathematical models of the key mechanisms.
This approach has not only proven successful with our own designs, but has also enabled TTP to support clients facing the scale-up problems that typically arise with less robust device development styles.
Melbourn Science Park
SG8 6EE UK
Tel: +44 1763 262626
Fax: +44 1763 261582
Registered number: 3304950
Registered office: as shown above
Country of registration: England & Wales
VAT number: 636 9859 76
The Technology Partnership plc is a TTP Group plc company.
© 2018 The Technology Partnership. All rights reserved.